Mediwound Reports Top-Line Results from Phase 2 Study with EscharEx to Treat Chronic Wounds Will Be Presented at Symposium on Advanced Wound Care

MediWound Ltd.

, a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that top-line data from a multicenter Phase 2 clinical study of the Company's EscharEx® to treat chronic wounds will be presented in the Late-Breaking Session at the Spring Symposium on Advanced Wound Care (SAWC) 2016 taking place April 13-17, 2016 in Atlanta. "We are excited that these positive data will be presented at SAWC Spring 2016 before an audience of the world's leading wound care clinicians. The top-line data from this multicenter, international, prospective, randomized, vehicle-controlled, assessor-blinded Phase 2 trial are important because there has been a long-lasting, unmet medical need for an effective and rapid nonsurgical debridement treatment for chronic wounds. Debridement is a critical first step to facilitate wound management and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound," noted Gal Cohen, MediWound's Chief Executive Officer. "The incidence of complete debridement with EscharEx within up to 10 daily treatments was significantly higher and completed earlier compared with the control group, with an overall comparable safety profile. Results were even more prominent in the prospective subgroups of diabetic foot and venous leg ulcers, which is in line with the etiologies we are focused on based on the results of a comprehensive market research report we undertook. The topical debridement treatments currently on the market require daily application for weeks and months to achieve complete debridement. A post hoc analysis of our Phase 2 data with EscharEx showed that 93% of the wounds which completed debridement with EscharEx were debrided within 7 days after 4-5 applications on average," added Mr. Cohen. The poster highlighting the top-line results of the Phase 2 study of EscharEx to treat chronic wounds will be available for viewing Friday, April 15th and Saturday, April 16th from 7:30 a.m. to 6:00 p.m. local time. The study authors will present the data during the following session: Session: Wound Healing Society's Poster Presentations Title: "Bromelain-based Enzymatic Debridement of Chronic Wounds: Top-Line Results of a Multicenter Phase 2 Trial" Authors: Y. Shoham, MD, Plastic and Reconstructive Surgery Department, Soroka University Medical Center, Beer Sheva, Israel; A. Shalom, M. D., Plastic and Reconstructive Surgery Department, Meir Medical Center, Kfar Saba, Israel; L. Rosenberg, MD, MediWound Poster # P.CC02 Date/Time: Friday, April 15 from 7:15 p.m. – 8:30 p.m. On February 3, 2016, MediWound announced the top-line results from the Phase 2 clinical trial of EscharEx to treat chronic wounds. A summary of those data can be found here.